(0.16%) 5 108.17 points
(0.17%) 38 304 points
(0.17%) 15 954 points
(-1.03%) $82.99
(4.84%) $2.02
(0.06%) $2 348.70
(0.14%) $27.57
(4.03%) $959.30
(-0.19%) $0.933
(-0.27%) $11.00
(-0.45%) $0.797
(1.73%) $93.46
@ $54.30
发出时间: 26 Apr 2024 @ 21:49
回报率: 1.84%
上一信号: Apr 26 - 21:32
上一信号:
回报率: 1.93 %
Live Chart Being Loaded With Signals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform...
Stats | |
---|---|
今日成交量 | 609 317 |
平均成交量 | 1.72M |
市值 | 4.69B |
EPS | $0 ( 2024-02-20 ) |
下一个收益日期 | ( $-1.630 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.51 |
ATR14 | $1.497 (2.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Kulkarni Samarth | Buy | 19 582 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 18 378 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 1 204 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 19 582 | Stock Option (Right to Buy) |
2024-03-20 | Kasinger James R. | Buy | 33 333 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
63.61 |
Last 100 transactions |
Buy: 2 415 277 | Sell: 542 570 |
音量 相关性
CRISPR Therapeutics AG 相关性 - 货币/商品
CRISPR Therapeutics AG 财务报表
Annual | 2023 |
营收: | $370.00M |
毛利润: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2023 |
营收: | $370.00M |
毛利润: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2022 |
营收: | $436 000 |
毛利润: | $-109.81M (-25 186.70 %) |
EPS: | $-8.36 |
FY | 2021 |
营收: | $914.96M |
毛利润: | $914.96M (100.00 %) |
EPS: | $4.97 |
Financial Reports:
No articles found.
CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。